BVF Partners L.P. is a San Francisco-based private investment partnership founded in 1993 by Mark N. Lampert, specializing in fundamentally-driven investments in small- to mid-cap biotechnology and pharmaceutical companies. The firm employs an active, research-based engagement approach across both private and public biotech investments.
76% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (2 deals in the last 12 months vs 5 prior). Average disclosed round size is $179.7M (across 25 rounds with reported amounts).
Portfolio
28
Fund Size
—
Top Stage
Series B
Last 12 Mo
2
Team
MM
Michael Murray
Managing Director
SL
Spike Loy
Managing Director
TN
Thor Nagel
Biotech Investor
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
29 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Ambrosia Biosciences Inc. | Series B | $100M | Mar 2026 |
 Third Arc Bio | Series A | $52M | Feb 2026 |
 Crescent Biopharma | Growth | $200M | Jun 2025 |
 RAPT Therapeutics | Series D | $150M | Dec 2024 |
 Elektrofi, Inc. | Series C | $112.3M | Oct 2024 |
 Alpha-9 Oncology | Series C | $175M | Oct 2024 |
 Inventiva | Unknown | — | Oct 2024 |
 Pheon Therapeutics | Series B | $120M | May 2024 |
 AltruBio | Series B | $225M | May 2024 |
 Cidara Therapeutics | Unknown | $240M | Apr 2024 |
 Diagonal Therapeutics | Series A | $128M | Apr 2024 |
 Aro Biotherapeutics | Series B | $41.5M | Nov 2023 |
 Forward Therapeutics | Series A | $50M | Nov 2023 |
 Alpha9Tx | Series B | $75M | Dec 2022 |
 Ventus | Series C | $140M | Feb 2022 |
 Nimbus | Unknown | $125M | Jan 2022 |
 TYRA Biosciences | Series B | $106M | Mar 2021 |
 EQRx | Growth | $1.8B | Jan 2021 |
| OOlema Oncology | Series C | $85M | Oct 2020 |
 Olema Pharmaceuticals Inc | Series C | $85M | Oct 2020 |
| 44DMT | Series C | $75M | Jun 2020 |
 Autobahn Therapeutics | Series B | $76M | Jun 2020 |
| Aro Biotherapeutics | Series A | — | Jan 2020 |
| ZZiarco | Series B | $33.1M | Jan 2014 |
| VVentus Therapeutics | Series C | — | — |
Page 1 of 2
Top Co-Investors
RA Capital Management13 shared
Perceptive Advisors7 shared
Samsara BioCapital6 shared
OrbiMed5 shared
Logos Capital5 shared
Deep Track Capital5 shared
Cormorant Asset Management5 shared
Alexandria Venture Investments5 shared
Atlas Venture4 shared
Nextech Invest Ltd.4 shared
Frazier Life Sciences4 shared
Canaan Partners4 shared
Bain Capital Life Sciences4 shared
Viking Global Investors4 shared
Casdin Capital4 shared
Pfizer Ventures4 shared
Lightspeed Venture Partners3 shared
Wellington Management3 shared
Foresite Capital3 shared
Last updated: 8 September 2026